




>>Entry Name: Indinavir, BAN, INN, USAN

Synonym(s): *N*-(2,3-Dihydro-2-hydroxy-1*H*-inden-1-yl)-2-[[[(1,1-dimethylethyl)amino]carbonyl]- γ -hydroxy- α -phenylmethyl-4-(3-pyridinylmethyl)-1-piperazine]pentonamide, 9Cl. L-735524



CAS Registry Number: 150378-17-9

Molecular Formula: C₃₆H₄₇N₅O₄

Molecular Weight: 613.798

Accurate Mass: 613.362805

Percentage Composition: C 70.45%; H 7.72%; N 11.41%; O 10.43%

Biological Use/Importance: HIV-1 protease inhibitor. Antiviral agent

Physical Description: Cryst. + H₂O (EtOAc aq.)

Development Status: Marketed drug. Launched 1996 (US). Worldwide 95th best selling prescription drug (as Crixivan) (\$0.53 bn) (Merck) (2000, Pharma Business)

Melting Point: Mp 167.5-168° (153-154°) (anhyd.)

Optical Rotation: [α]_D²²+24.1 (c, 0.1 in CHCl₃)

>>Derivative: Sulfate

Synonym(s): Crixivan. MK 639

CAS Registry Number: 157810-81-6

Physical Description: Cryst. + 1EtOH (EtOH)

Melting Point: Mp 150-153 dec.°

References:

- Eur. Pat.*, 1993, *Merck*, 541 168; *CA*, **120**, 54552w
Dorsey, B.D. *et al.*, *J. Med. Chem.*, 1994, **37**, 3443, (*synth*)
Vacca, J.P. *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 1994, **91**, 4096, (*pharmacokinet*)
Askin, D. *et al.*, *Tet. Lett.*, 1994, **35**, 673, (*synth*)
Balani, S.K. *et al.*, *Drug Metab. Dispos.*, 1995, **23**, 266, (*metab*)
Woolf, E. *et al.*, *J. Chromatogr., A*, 1995, **692**, 45, (*hplc*)
Condra, J.H. *et al.*, *Nature (London)*, 1995, **374**, 569, (*pharmacol*)
Maligres, P.E. *et al.*, *Tet. Lett.*, 1995, **36**, 2195, (*cryst struct*)
Emini, E.A. *et al.*, *Adv. Exp. Med. Biol.*, (Antiviral Chemotherapy 4), 1996, **394**, 327, (*rev*)
Ohta, Y. *et al.*, *Bioorg. Med. Chem.*, 1997, **5**, 463-464, (*rev*)
Koudriakova, T. *et al.*, *Drug Metab. Dispos.*, 1998, **26**, 552-561, (*metab*)
Tawa, G.J. *et al.*, *J.A.C.S.*, 1998, **120**, 8856-8863, (*drug-enzyme binding*)
Martindale, The Extra Pharmacopoeia, 32nd edn., *Pharmaceutical Press*, 1999, 614